Table 1. Patient characteristics.
| (Neo) adjuvant CT | 1st pall. CT | 2nd pall. CT | 3rd+ pall. CT | |
|---|---|---|---|---|
|
Number of patients |
n=46 |
n=146 |
n=55 |
n=22 |
|
Age | ||||
| Mean (s.d.) |
64.3 (8.7) |
68.3 (10.4) |
67.6 (9.1) |
66.2 (8.7) |
|
Sex | ||||
| Men | 64.1% | 63.9% | 64.1% | 47.9% |
| Women |
35.9% |
36.1% |
35.9% |
52.1% |
|
Diagnosis | ||||
| NSCLC | 78.8% | 84.3% | 90.0% | 90.4% |
| SCLC |
21.2% |
15.7% |
10.0% |
9.6% |
|
Time since diagnosisa | ||||
| Mean (s.d.) |
2.2 (1.3) |
4.6 (7.5) |
17.8 (17.0) |
20.4 (13.5) |
|
Tumour stage | ||||
| I | 19.8% | 3.4% | 3.1% | 0% |
| II | 17.7% | 0% | 4.1% | 0% |
| III | 51.0% | 27.5% | 22.4% | 7.2% |
| IV |
11.5% |
69.1% |
70.4% |
92.8% |
|
Previous surgery | ||||
| Yes |
43.5% |
22.1% |
32.1% |
30.9% |
|
Metastasis | ||||
| Yes |
42.8% |
69.9% |
82.0% |
73.6% |
|
Chemotherapy regimen | ||||
| NSCLC monotherapy Gemcitabine, Docetaxel, Vinorelbine, Palitaxel, Pemetrexed | 12.3% | 20.7% | 82.4% | 84.9% |
| NSCLC platin combination therapy Vinorelbine (+antibodies), Gemcitabine Pemetrexed, Docetaxel, respectively+platines | 64.4% | 63.6% | 7.1% | 7.5% |
| SCLC platin combination therapy Etoposide+platines, Cisplatin/Irinotecan | 23.3% | 12.8% | 0.0% | 3.2% |
| SCLC non-platin therapy CAV, Topotecan | 0.0% | 2.9% | 10.6% | 4.3% |
Abbreviations: CT=chemotherapy; NSCLC=non-small-cell lung carcinoma; pall.=palliative; SCLC=small-cell lung carcinoma.
Total N=187. Sixty three patients were accounted for two, and 14 patients for three or more chemotherapy lines because they passed from one line to another.
a
Number of months that passed since diagnosis, averaged across all assessments within a CT line.